NCT07472387 2026-03-16
Andro-iGlio
Assistance Publique - Hôpitaux de Paris
Phase NA Not yet recruiting
Clinical Trials
18 trialsNCT07398170 2026-02-09
BIOLIMEN-1
University Hospital, Montpellier
Phase NA Not yet recruiting
NCT03526822 2026-01-28
MM-Predict
Assistance Publique Hopitaux De Marseille
Phase NA Recruiting
NCT05212272 2026-01-22
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Wake Forest University Health Sciences
Phase NA Recruiting
NCT07211841 2025-11-19
GLIOMIT
Centre Hospitalier Universitaire, Amiens
Phase NA Not yet recruiting
NCT05133154 2025-07-11
GLIOLIPSY
University Hospital, Montpellier
Phase NA Recruiting
NCT04025541 2025-04-02
ALCINA2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT06618703 2025-02-25
BIChE-1
University Hospital, Angers
Phase NA Not yet recruiting
NCT06764537 2025-01-08
BOOSTCAR
Central Hospital, Nancy, France
Phase NA Not yet recruiting
NCT06116903 2024-12-13
ExoGLIE
University Hospital, Limoges
Phase NA Recruiting
NCT02864563 2023-12-01
PHRCNB07
Institut Curie
Phase NA Completed
NCT05793021 2023-03-31
FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Unknown
NCT03986853 2022-08-04
Explor-AVD
Hopital Foch
Phase NA Terminated
NCT05099068 2022-07-05
PLANET
Centre Leon Berard
Phase NA Unknown
NCT03787056 2021-07-16
ONCOPRO
Hospices Civils de Lyon
Phase NA Recruiting
NCT01674582 2020-09-03
Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters
Lund University Hospital
Phase NA Completed
NCT02041611 2018-06-27
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT00897611 2012-11-30
Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed